A randomized, double-blinded, parallel-controlled clinical study to investigate the blood glucose fluctuation of mulberry twig (Ramulus Mori, Sangzhi) alkaloid tablet and NovoMix30 in patients with Type 2 Diabetes Mellitus

Start Date01 Aug 2022

Sponsor / Collaborator-

CTRI/2022/06/043169

/ CompletedPhase 1

A Randomized, Double Blind, Single Center, Two Treatment, Two-Period, TwoSequence, Crossover, Euglycemic clamp study to demonstrate equivalence in thePharmacokinetic and Pharmacodynamic properties of Insulin Aspart Mix 30 ofBioGenomics Limited and NovoMix® 30 of Novo Nordisk in healthy, adult, humanmale subjects under fasting condition.

Start Date14 Jun 2022

Sponsor / Collaborator

BioGenomics Ltd.

NCT03862690

/ WithdrawnNot Applicable

A Prospective Non-interventional Study Investigating the Treatment Effect of NovoMix® 30 (Biphasic Insulin Aspart 30) in a Real World Adult Population With Type 2 Diabetes in Algeria

The purpose of the study is to collect information about how NovoMix® 30 works in real world adult population with type 2 diabetes. Participants will get NovoMix® 30 as prescribed by the study doctor. The study will last for about 6-8 months. Participants will be asked questions about their health and their diabetes treatment as part of their study doctor's appointment.

Start Date28 May 2020

Sponsor / Collaborator

Novo Nordisk A/S

100 Clinical Results associated with Insulin aspart/insulin protamine aspart(Novo Nordisk)

100 Translational Medicine associated with Insulin aspart/insulin protamine aspart(Novo Nordisk)

100 Patents (Medical) associated with Insulin aspart/insulin protamine aspart(Novo Nordisk)

161

Literatures (Medical) associated with Insulin aspart/insulin protamine aspart(Novo Nordisk)

01 May 2024·Diabetic medicine : a journal of the British Diabetic Association

Real‐world study of the concomitant use of biphasic insulin aspart 30/70 with GLP‐1 receptor agonist versus first‐generation basal insulin with GLP‐1 receptor agonist in type 2 diabetes

Article

Author: Jensen, Anders Boeck ; Anil, Gayathri ; Davies, Melanie ; Braae, Uffe Christian ; Nordsborg, Rikke Baastrup ; Alibegovic, Amra Ciric

Abstract:

Aims:

Combining insulin with a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) to treat type 2 diabetes (T2D) is common. While many studies have investigated concomitant therapy with basal insulin+GLP‐1RA, few have reported on premixed insulin+GLP‐1RA. We aimed to address this gap using data from the Clinical Practice Research Datalink Aurum database in England.

Methods:

This retrospective cohort study with propensity score matching assessed glycaemic levels and other clinical outcomes in people with T2D, comparing biphasic insulin aspart 30/70 (BIAsp 30) + GLP‐1RA with basal insulin (insulin detemir/glargine U100) + GLP‐1RA (from 2006 to 2021).

Results:

In total, 4770 eligible people were identified; 1511 had a BIAsp 30 + GLP‐1RA regimen and were propensity score‐matched to an equal number receiving basal+GLP‐1RA. There was no significant difference in glycated haemoglobin (HbA1c) reduction between cohorts at 6 months (p = 0.15), with a decrease of −1.07 (95% CI: −1.16; −0.98) %‐points (−11.7 mmol/mol [95% CI: −12.7; –10.7]) in the BIAsp 30 + GLP‐1RA cohort, versus −0.97 (95% CI: −1.07; −0.88) %‐points (−10.6 mmol/mol [95% CI: −11.7; –9.6]) in the basal+GLP‐1RA cohort. Body mass index (BMI) decreased by −0.35 kg/m2 (95% CI: −0.52;−0.18) at 6 months with BIAsp 30 + GLP‐1RA, versus −0.72 kg/m2 (95% CI: −0.90;−0.54) with basal+GLP‐1RA (p = 0.003). BMI was influenced by the initiation sequence of GLP‐1RA in relation to insulin (p < 0.0001). Hypoglycaemia rates were low and not significantly different between cohorts.

Conclusions:

Combining BIAsp 30 + GLP‐1RA provides glycaemic control with no significant difference to that of propensity score‐matched people receiving basal insulin+GLP‐1RA, with no increase in hypoglycaemia risk or weight gain.

01 Dec 2023·Internal medicine journal

Mixed insulin can improve control of prednisolone‐induced hyperglycaemia

Article

Author: Sztal-Mazer, Shoshana ; Scholes, Gemma ; Bach, Leon A ; Ng, Elisabeth

Abstract:

Background:

Hyperglycaemia is a common side effect of prednisolone, although there are no widely accepted guidelines for the management of glucocorticoid‐induced hyperglycaemia (GIH). Our institution uses mixed insulin in a pre‐breakfast or pre‐breakfast and pre‐lunch regimen, with the rationale that this profile of insulin action matches the physiological effect of prednisolone on blood glucose levels (BGLs).

Aim:

Evaluate the use of the mixed insulin (NovoMix30) in a pre‐breakfast or pre‐breakfast and pre‐lunch regimen as management for GIH in a tertiary hospital setting.

Method:

We retrospectively evaluated all inpatients coprescribed prednisolone ≥7.5 mg and NovoMix30 for at least 48 hours over a 19‐month period. BGLs were evaluated with repeated‐measures analysis within four time periods across the day, beginning from the day prior to NovoMix30 administration.

Results:

A total of 53 patients were identified. NovoMix30 significantly reduced BGLs in the morning (mean 12.7 ± 4.5 vs. 9.2 ± 3.9 mmol/L, P < 0.001), afternoon (mean 13.6 ± 3.8 vs. 11.9 ± 3.8 mmol/L, P = 0.001) and evening (12.1 ± 3.8 vs. 10.8 ± 3.8 mmol/L, P = 0.01). With uptitration of insulin over 3 days, 43% of all BGLs were within the target range, compared with 23% on day 0 (P < 0.001). The final median dose of NovoMix30 was 0.15 (0.10–0.22) units/kg bodyweight, or 0.40 (0.23–0.69) units/mg of prednisolone, which is lower than our hospital guideline recommends. One overnight hypoglycaemic event was observed.

Conclusion:

Mixed insulin as a pre‐breakfast or pre‐breakfast and pre‐lunch regimen can target the hyperglycaemic pattern induced by prednisolone and minimise overnight hypoglycaemia. However, higher doses of insulin than those used in our study are likely required for optimal BGL control.

01 Sep 2023·Diabetes, obesity & metabolism

Advancing therapy in people with suboptimally controlled basal insulin-treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries.

Article

Author: Anguiano, Luis ; Choza-Romero, Ricardo ; Frechtel, Gustavo ; Sañudo-Maury, María Elena ; Melas-Melt, Lydie ; Sauque-Reyna, Leobardo

AIMS:

This subanalysis of the SoliMix trial assessed the efficacy and safety of advancing basal insulin (BI) therapy with iGlarLixi versus BIAsp 30 in people with type 2 diabetes (T2D) living in Latin American (LATAM) countries, i.e. Argentina and Mexico (N = 160).

MATERIALS AND METHODS:

SoliMix (EudraCT: 2017-003370-13) was a 26-week, open-label, multicentre study, where adults with T2D suboptimally controlled with BI plus one or two oral glucose-lowering drugs and glycated haemoglobin (HbA1c) ≥7.5% to ≤10% were randomized to once-daily iGlarLixi or twice-daily BIAsp 30. Primary efficacy endpoints were non-inferiority in HbA1c reduction (margin 0.3%) or superiority in body weight change for iGlarLixi versus BIAsp 30.

RESULTS:

Both primary efficacy endpoints were met in the LATAM region. After 26 weeks, HbA1c was reduced by 1.8% with iGlarLixi and 1.4% with BIAsp 30, meeting non-inferiority [least squares mean difference -0.47% (95% confidence interval: -0.82, -0.11); p < .001]. iGlarLixi was superior to BIAsp 30 for body weight change [least squares mean difference -1.27% (95% confidence interval: -2.41, -0.14); p = .028]. iGlarLixi was also superior to BIAsp 30 for HbA1c reduction (p = .010). A greater proportion of participants achieved HbA1c <7% without weight gain and HbA1c <7% without weight gain and without hypoglycaemia with iGlarLixi versus BIAsp 30. Incidence and rates of American Diabetes Association Level 1 and 2 hypoglycaemia were lower with iGlarLixi versus BIAsp 30.

CONCLUSIONS:

Once-daily iGlarLixi provided better glycaemic control with weight benefit and less hypoglycaemia than twice-daily premix BIAsp 30. iGlarLixi may be a favourable alternative to premix BIAsp 30 in people with suboptimally controlled T2D to advance BI therapy in the LATAM region.

News (Medical) associated with Insulin aspart/insulin protamine aspart(Novo Nordisk)

15 Mar 2023

·www.pharmaceutical-technology.com

Novo Nordisk to reduce US list prices of insulin products

Novo Nordisk has various long-standing US affordability offerings for eligible people living with diabetes. Credit: Novo Nordisk A/S. Novo Nordisk has announced plans to reduce the US wholesale acquisition cost (WAC), also known as the list price, of several pre-filled insulin pens and vials by up to 75% for people living with type 1 and type 2 diabetes. Set to come into effect from 1 January 2024, these changes will be applicable for products including pre-filled pens and vials of basal (long-acting), bolus (short-acting) and pre-mix insulins, Levemir, Novolin, NovoLog and NovoLog Mix 70/30 in specific. Novo Nordisk Market Access & Public Affairs senior vice-president Steve Albers said: “We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes. “Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously.” The company will reduce the list price of four legacy insulin brands, including NovoLog and NovoLog Mix 70/30 by 75%, and Novolin and Levemir by 65% off the current list price. Additionally, the list price of unbranded biologics (pre-filled pens and vials and pre-mix insulins) is being reduced to match the lowered price of each respective branded insulin (Insulin Aspart and Insulin Aspart Protamine/Insulin Aspart). Novo Nordisk also has various long-standing US affordability offerings for eligible people who are living with diabetes. They include Unbranded Biologics, the Novo Nordisk Human Insulin programme, Co-pay Savings Cards, My$99Insulin, Immediate Supply, A Patient Assistance Program (PAP) and the Covid-19 Patient Assistance Program. Working with a diverse group of stakeholders, Novo Nordisk said it will understand the emerging needs of patients.

14 Mar 2023

·medcitynews.com

Novo Nordisk Follows Eli Lilly’s Lead, Lowering Insulin Prices up to 75%

Novo Nordisk is slashing prices of several insulin products by up to 75% amid growing political scrutiny on the prices of these older but still expensive diabetes medicines. The announcement Tuesday comes two weeks after rival Eli Lilly unveiled price cuts for its insulin products, but unlike Lilly’s new pricing, which will start this spring for some products, Novo Nordisk’s new insulin prices won’t take effect until 2024. The Novo Nordisk products covered under the new list prices include the long-acting insulins Levemir and Novolin, which will see 65% price cuts. Levemir will cost $107.85 per vial and $161.77 for product dosed with the FlexPen delivery system. Novolin will cost $48.20 per vial and $91.09 per FlexPen. The fast-acting insulin products Novolog and Novolog Mix 70/30 will see 75% price cuts to $72.34 per vial, $139.71 per FlexPen. Denmark-based Novo Nordisk, which maintains a U.S. headquarters in Plainsboro, New Jersey, also said it will reduce the list price for unbranded biologics to match the lower price of the corresponding branded insulin. Unbranded biologics are the branded product marketed under a different name. The lower prices cover Insulin Aspart, which is the unbranded biologic of Novolog, and Insulin Aspart Protamine/Insulin Aspart, which is unbranded Novolog Mix 70/30. Novo Nordisk can afford to cut insulin prices because it is seeing rapid growth from other products. While the company’s insulins are blockbuster sellers, their sales growth has flattened. The company reported 38.7 billion Danish krone (about $5.6 billion) in 2022 revenue for all of its insulin products, down nearly 3% from the prior year and just 1% higher compared to two years ago. Meanwhile, the drugmaker is seeing strong sales growth from diabetes and obesity medications in its semaglutide franchise. Ozempic, a type 2 diabetes drug that works by activating the GLP-1 receptor, is far and away Novo Nordisk’s largest single product with 17.3 billion Danish krone (about $2.5 billion) in 2022 sales, up more than 96% from the prior year. Rybelsus, a GLP-1-targeting drug that like Ozempic, contains semaglutide but in an oral formulation, posted 3.1 billion Danish krone (about $455 million) in sales last year, a more than 500% increase over 2021 sales. In January, the FDA expanded Rybelsus’s approval to include first-line treatment of type 2 diabetes. Permitting the drug for use as an earlier treatment further expands the market for the product. Novo Nordisk is seeing strong demand for the semaglutide-containing weight-loss drug Wegovy, which won its FDA approval in mid-2021. Demand for Wegovy and Ozempic for use in treating obesity has strained the company’s manufacturing capacity, leading to shortages. The insulin market is dominated by three companies: Eli Lilly, Novo Nordisk, and Sanofi. Since Eli Lilly’s announcement at the beginning of March that it would cut list prices for its insulin products by up to 70%, some lawmakers have been calling on Novo Nordisk and Sanofi to do the same. A $35 per month price cap on insulin went into effect at the beginning of this year, but only for Medicare beneficiaries. That price cap was one of the provisions of the wide-ranging Inflation Reduction Act. Lilly’s pricing announcement extended the monthly cap to all insured diabetes patients who take the pharmaceutical company’s insulins. Those who aren’t covered by health insurance may enroll in a program that makes all of Lilly’s insulins available for $35 a month. Novo Nordisk said that it currently offers co-pay savings cards for patients covered by commercial insurance plans. These cards enable eligible patients to pay monthly co-pays of $25 to $35 for several of the company’s insulin products. In its announcement, Novo Nordisk said it has been working to identify “a sustainable approach to reduce insulin costs for patients that addresses changes in health policy and market shifts.” “We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes,” Steve Albers, Novo Nordisk’s senior vice president of market Access and public affairs, said in a prepared statement. “Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously.” Photo by Jean-Francois Monier/AFP, via Getty Images

Drug Approval

14 Mar 2023

·www.biospace.com

Novo Nordisk to lower U.S. prices of several pre-filled insulin pens and vials up to 75% for people living with diabetes in January 2024

Novo Nordisk has been working to identify a sustainable approach to reduce insulin costs for patients that addresses changes in health policy and market shifts Lower list prices build on long-standing history of affordability initiatives already in place which can be accessed at NovoCare.com Novo Nordisk currently provides co-pay support for a number of insulin products meaning eligible patients can pay $25-35 for their insulin PLAINSBORO, N.J., March 14, 2023 /PRNewswire/ -- Novo Nordisk Inc. today announced it is lowering the U.S. list prices of several insulin products by up to 75% for people living with type 1 and type 2 diabetes. Products include both pre-filled pens and vials of basal (long-acting), bolus (short-acting) and pre-mix insulins, specifically Levemir®, Novolin®, NovoLog® and NovoLog® Mix 70/30. Novo Nordisk is also reducing the list price of unbranded biologics to match the lowered price of each respective branded insulin. These changes will go into effect on January 1, 2024. Novo Nordisk recognizes that some patients find it difficult to pay for healthcare, including insulin. As such, the Company remains committed to reducing the burden of out-of-pocket costs, helping transform the complex pricing system, and fostering better pricing predictability. Novo Nordisk continually reviews and revises our offerings as well as works with diverse stakeholders to create solutions for differing patient needs. "We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president, Market Access & Public Affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously." The following changes to the wholesale acquisition cost (WAC), also known as the list price, will take effect on January 1, 2024: Lowering the list price of four legacy insulin brands, including NovoLog® and NovoLog® Mix 70/30 by 75% off the current list price, and Novolin® and Levemir® by 65% off the current list price. New prices of these products will be as follows: NovoLog® & NovoLog® Mix 70/30 Levemir® Novolin® Vial $72.34 $107.85 $48.20 FlexPen® $139.71 $161.77 $91.09 Reducing the list price of the following unbranded biologics (pre-filled pens and vials and pre-mix insulins) to match the lowered price of each respective branded insulin: Insulin Aspart and Insulin Aspart Protamine/Insulin Aspart. Additionally, Novo Nordisk has a variety of long-standing U.S. affordability offerings available to eligible people living with diabetes, including: Unbranded Biologics: Insulin Degludec is currently available at 65% off the list price of Tresiba®; Insulin Aspart and Insulin Aspart Protamine/Insulin Aspart are currently available at 50% off the list price of NovoLog® and NovoLog® Mix. Novo Nordisk Human Insulin: A program through Walmart for more than two decades offers human insulin for approximately $25 per vial; it is also available at CVS for $25. Co-pay Savings Cards: Co-pays for as little as $25-35 for several insulin products for eligible patients in commercial insurance plans. My$99Insulin: A 30-day supply of a combination of insulin products (up to three vials or two packs of pens) for $99, equating to $33/vial or $49.50/pack of pens. Immediate Supply: A one-time free 30-day supply of insulin (up to three vials or two packs of pens) to eligible patients at risk of rationing. A Patient Assistance Program (PAP): Offers free diabetes medication to people in need who meet certain eligibility criteria. COVID-19 Patient Assistance Program: Offers 90 days of free insulin to eligible patients who lost healthcare coverage due to COVID-19 job loss. Novo Nordisk will continue to work with a diverse group of stakeholders to understand emerging patient needs. People living with diabetes are encouraged to access and learn more about these affordability programs at NovoCare.com. Please visit mynovoinsulin.com for more important information about Novo Nordisk Inc. insulins. About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity and rare blood and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term and do business in a financially, socially, and environmentally responsible way. With U.S. headquarters in New Jersey and production and research facilities in seven states, Novo Nordisk employs nearly 6,000 people throughout the country. For more information, visit novonordisk-us.com, Facebook, Instagram, and Twitter. Company Codes: NYSE:NVO

Acquisition

100 Deals associated with Insulin aspart/insulin protamine aspart(Novo Nordisk)

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus	United States	Novo Nordisk, Inc.	01 Nov 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Insulin-Dependent, 2	Phase 3	China	Novo Nordisk A/S	08 Jul 2003
Diabetes Mellitus, Type 1	Phase 3	Austria	Novo Nordisk A/S	01 Apr 1998
Diabetes Mellitus, Type 1	Phase 3	Germany	Novo Nordisk A/S	01 Apr 1998
Diabetes Mellitus, Type 1	Phase 3	Ireland	Novo Nordisk A/S	01 Apr 1998
Diabetes Mellitus, Type 1	Phase 3	Switzerland	Novo Nordisk A/S	01 Apr 1998
Diabetes Mellitus, Type 1	Phase 3	United Kingdom	Novo Nordisk A/S	01 Apr 1998
Diabetes Mellitus, Type 2	Phase 3	Austria	Novo Nordisk A/S	01 Apr 1998
Diabetes Mellitus, Type 2	Phase 3	Germany	Novo Nordisk A/S	01 Apr 1998
Diabetes Mellitus, Type 2	Phase 3	Ireland	Novo Nordisk A/S	01 Apr 1998
Diabetes Mellitus, Type 2	Phase 3	Switzerland	Novo Nordisk A/S	01 Apr 1998

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03374774 (Pubmed \| Pharmacoecon Open)	Not Applicable	Diabetes Mellitus, Type 2	505	BIAsp 30 in an insulin pen (FlexPen® or Penfill® device)	ncgydlkjpk(pddhusnozs) = qihgxygojt jnfincnnrf (knxusxwrqa, 383 - 994)	-	06 Jan 2021
NCT00821795 (VIISTA, CTgov)	Phase 4	Diabetes Mellitus, Type 2	120	NPH/Regular 70/30 mix (NPH/Regular 70/30 Mix)	qnfrgucsac(aqqcdrpfmk) = unfqkbqrad iqghktlupb (mvpiwzzozw, 1.5) View more	-	04 Mar 2020
				insulin aspart protamine/insulin aspart 70/30 mix (Aspart Insulin Analog Biphasic Mix)	qnfrgucsac(aqqcdrpfmk) = snruzcreqf iqghktlupb (mvpiwzzozw, 1.95) View more
NCT02453685 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	335	Insulin+metformin+BIAsp 30 (BIAsp 30)	jmxgiztlsh(aziuvbqntc) = qainsdeaye pdyhzlqcwh (aeacuwyrjo, 0.98) View more	-	08 Feb 2019
				Insulin+metformin (Basal-bolus)	jmxgiztlsh(aziuvbqntc) = rasfpstaxd pdyhzlqcwh (aeacuwyrjo, 0.90) View more
NCT02582242 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	437	Insulin Aspart (Biphasic Insulin Aspart 30 (Three Times Daily))	wnxuoqyaoa(dybbjjzrfq) = hkttrdrpzt auetrxxpht (orikiefwng, 1.00) View more	-	29 May 2018
				Insulin Aspart (Biphasic Insulin Aspart 30 (Twice Daily))	wnxuoqyaoa(dybbjjzrfq) = uxigcoclbo auetrxxpht (orikiefwng, 0.94) View more
NCT01589653 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	155	biphasic insulin aspart 30 (Subject-driven Titration)	plydsfnnym(xhjtttgptj) = oremihdyhm porqiqawid (rputcedems, 0.11) View more	-	09 Aug 2016
				biphasic insulin aspart 30 (Investigator-driven Titration)	plydsfnnym(xhjtttgptj) = tdqkpcbqki porqiqawid (rputcedems, 0.11) View more
NCT01009580 (BOOST™, CTgov)	Phase 3	Diabetes Mellitus, Type 2	447	insulin degludec/insulin aspart (IDegAsp BID)	whnwpbmcqp(xqvoyoxect) = nvbpijrewv rwpfnaunvb (dysekvrdeq, 0.94) View more	-	20 Nov 2015
				biphasic insulin aspart 30 (BIAsp 30 BID)	whnwpbmcqp(xqvoyoxect) = ehebcnjngg rwpfnaunvb (dysekvrdeq, 0.97) View more
NCT01892020 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	161	BIAsp (BIAsp 50)	houibmuqrk(ctndhjxnre) = kusrzytmzq qsnaartonj (bawbtadmqw, 3.17) View more	-	09 Jul 2015
				BHI (BHI 50)	houibmuqrk(ctndhjxnre) = drufamhwot qsnaartonj (bawbtadmqw, 2.83) View more
NCT01519674 (Sit2Mix, CTgov)	Phase 4	Diabetes Mellitus, Type 2	582	Met (BID + Met)	oqdyfhlvqr(tsbjidmtyq) = anwynkppnm wuvaglzcji (phxfpjfcpf, 0.07) View more	-	10 Nov 2014
				Met (BID + Sita + Met)	oqdyfhlvqr(tsbjidmtyq) = ecaxvuesoi wuvaglzcji (phxfpjfcpf, 0.07) View more
NCT01618214 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	344	biphasic insulin aspart 30 (Subject-driven Titration)	hlhlxjoenh(irmmyfmzum) = pqtoravyvn tgltvzfbgo (dumyfimroz, 0.86) View more	-	08 May 2014
				biphasic insulin aspart 30 (Investigator-driven Titration)	hlhlxjoenh(irmmyfmzum) = jhdgicmwgq tgltvzfbgo (dumyfimroz, 0.96) View more
NCT01215435 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	245	biphasic insulin aspart 30 (Pre-breakfast BIAsp 30)	upbbufmivd(dsofsptkuj) = phvtqbtyvw pknulasxuh (vfqfqshwvx, 0.10) View more	-	25 Nov 2013
				biphasic insulin aspart 30 (Pre-dinner BIAsp 30)	upbbufmivd(dsofsptkuj) = bjivwblulm pknulasxuh (vfqfqshwvx, 0.10) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Insulin aspart/insulin protamine aspart(Novo Nordisk)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation